Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1968 1
1970 2
1971 3
1972 5
1973 6
1974 9
1975 12
1976 12
1977 13
1978 14
1979 6
1980 26
1981 15
1982 20
1983 26
1984 21
1985 15
1986 21
1987 20
1988 13
1989 11
1990 17
1991 12
1992 8
1993 25
1994 4
1995 14
1996 9
1997 4
1998 6
1999 4
2000 7
2001 1
2002 9
2003 1
2004 5
2005 4
2006 5
2007 11
2008 1
2009 4
2010 4
2011 8
2012 3
2013 6
2014 6
2015 3
2016 3
2017 4
2018 1
2019 1
2020 3
2021 1
2022 5
2023 2
2024 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

461 results

Results by year

Filters applied: . Clear all
Page 1
Effectiveness of nifedipine, labetalol, and hydralazine as emergency antihypertension in severe preeclampsia: a randomized control trial.
S D, Novri DA, Hamidy Y, Savira M. S D, et al. F1000Res. 2023 Apr 27;11:1287. doi: 10.12688/f1000research.125944.2. eCollection 2022. F1000Res. 2023. PMID: 37273965 Free PMC article. Clinical Trial.
A single dose administration, four, one, and three patients had 20% MAP reduction in nifedipine, labetalol, and hydralazine group. Three, seven, and one patient had a failure of reaching 20% MAP reduction even after receiving the third dose. The effectiveness of the drugs …
A single dose administration, four, one, and three patients had 20% MAP reduction in nifedipine, labetalol, and hydralazine group. Th …
A clinical trial with valproic acid and hydralazine in combination with gemcitabine and cisplatin followed by doxorubicin and dacarbazine for advanced hepatocellular carcinoma.
Liu YC, Su CW, Ko PS, Lee RC, Liu CJ, Huang YH, Gau JP, Liu JH. Liu YC, et al. Asia Pac J Clin Oncol. 2022 Feb;18(1):19-27. doi: 10.1111/ajco.13443. Epub 2020 Sep 22. Asia Pac J Clin Oncol. 2022. PMID: 32964588 Clinical Trial.
Chemotherapy modulated with valproic acid (VA) as a deacetylation inhibitor of histone and DNA damage response proteins, and hydralazine (HZ) as a DNA hypomethylating agent, hypothetically suppressing DNA repair, were used in phase II trial here for advanced HCC. ...
Chemotherapy modulated with valproic acid (VA) as a deacetylation inhibitor of histone and DNA damage response proteins, and hydralazine …
Combination Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD (HIDE): A Randomized, Placebo-Controlled, Pilot Trial.
Charytan DM, Hsu JY, Mc Causland FR, Waikar SS, Ikizler TA, Raj DS, Landis JR, Mehrotra R, Williams M, DiCarli M, Skali H, Kimmel PL, Kliger AS, Dember LM; Hemodialysis Novel Therapies Consortium. Charytan DM, et al. Kidney360. 2020 Oct 15;1(12):1380-1389. doi: 10.34067/KID.0004342020. eCollection 2020 Dec 31. Kidney360. 2020. PMID: 35372900 Free PMC article. Clinical Trial.
BACKGROUND: Combination therapy with isosorbide dinitrate (ISD) and hydralazine (HY) reduces heart failure mortality. The safety and tolerability in individuals requiring maintenance hemodialysis (HD) is unknown. ...
BACKGROUND: Combination therapy with isosorbide dinitrate (ISD) and hydralazine (HY) reduces heart failure mortality. The safety and …
Plasma norepinephrine and mortality.
Cohn JN. Cohn JN. Clin Cardiol. 1995 Mar;18(3 Suppl I):I9-12. doi: 10.1002/clc.4960181304. Clin Cardiol. 1995. PMID: 7743697 Free article. Review.
Data from the V-HeFT II show that at 2-year follow-up, a progressive rise of plasma norepinephrine was observed in both treatment arms, suggesting that disease progresses despite treatment with either an angiotensin-converting enzyme inhibitor, enalapril, or vasodilator therapy w …
Data from the V-HeFT II show that at 2-year follow-up, a progressive rise of plasma norepinephrine was observed in both treatment arms, sugg …
Effect of fixed-dose combination of isosorbide dinitrate and hydralazine on all hospitalizations and on 30-day readmission rates in patients with heart failure: results from the African-American Heart Failure Trial.
Anand IS, Win S, Rector TS, Cohn JN, Taylor AL. Anand IS, et al. Circ Heart Fail. 2014 Sep;7(5):759-65. doi: 10.1161/CIRCHEARTFAILURE.114.001360. Epub 2014 Jun 26. Circ Heart Fail. 2014. PMID: 24970468 Clinical Trial.
BACKGROUND: Fixed-dose combination of isosorbide dinitrate and hydralazine (FDC-I/H) reduced mortality by 43% and death or first hospitalization for heart failure (HF) by 37% in the African-American Heart Failure Trial (A-HeFT). ...
BACKGROUND: Fixed-dose combination of isosorbide dinitrate and hydralazine (FDC-I/H) reduced mortality by 43% and death or first hosp …
Comparison of intravenous labetalol and hydralazine for severe hypertension in pregnancy in Northeastern Nigeria: A randomized controlled trial.
Muhammad S, Usman H, Dawha YM, Yahya A, Yekeen A, Bako B. Muhammad S, et al. Pregnancy Hypertens. 2022 Aug;29:1-6. doi: 10.1016/j.preghy.2022.05.001. Epub 2022 May 8. Pregnancy Hypertens. 2022. PMID: 35605426 Clinical Trial.
Hydralazine, however, produced a more marked reduction in diastolic blood pressure than labetalol (p = 0.012). CONCLUSION: Both labetalol and hydralazine are effective for acute blood pressure control in pregnancy with a similar safety profile. ...
Hydralazine, however, produced a more marked reduction in diastolic blood pressure than labetalol (p = 0.012). CONCLUSION: Both labet …
Severe hypertension in pregnancy: hydralazine or labetalol. A randomized clinical trial.
Vigil-De Gracia P, Lasso M, Ruiz E, Vega-Malek JC, de Mena FT, López JC; or the HYLA treatment study. Vigil-De Gracia P, et al. Eur J Obstet Gynecol Reprod Biol. 2006 Sep-Oct;128(1-2):157-62. doi: 10.1016/j.ejogrb.2006.02.015. Epub 2006 Apr 18. Eur J Obstet Gynecol Reprod Biol. 2006. PMID: 16621226 Clinical Trial.
No significant differences were observed for maternal hypotension or persistent severe hypertension; only two patients in the hydralazine group presented with hypotension. Palpitations (p=0.01) and maternal tachycardia (p=0.05) occurred significantly more often in patients …
No significant differences were observed for maternal hypotension or persistent severe hypertension; only two patients in the hydralazine …
Ketanserin and hydralazine in hypertension in pregnancy--a randomised double-blind trial.
Rossouw HJ, Howarth G, Odendaal HJ. Rossouw HJ, et al. S Afr Med J. 1995 Jun;85(6):525-8. S Afr Med J. 1995. PMID: 7652635 Clinical Trial.
OBJECTIVES: To compare ketanserin with hydralazine in the treatment of hypertension in late pregnancy. STUDY DESIGN: Randomised control trial. ...As ketanserin could become an alternative to hydralazine, more studies with larger numbers of patients are needed to com …
OBJECTIVES: To compare ketanserin with hydralazine in the treatment of hypertension in late pregnancy. STUDY DESIGN: Randomised contr …
Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial.
Candelaria M, Herrera A, Labardini J, González-Fierro A, Trejo-Becerril C, Taja-Chayeb L, Pérez-Cárdenas E, de la Cruz-Hernández E, Arias-Bofill D, Vidal S, Cervera E, Dueñas-Gonzalez A. Candelaria M, et al. Ann Hematol. 2011 Apr;90(4):379-87. doi: 10.1007/s00277-010-1090-2. Epub 2010 Oct 5. Ann Hematol. 2011. PMID: 20922525 Clinical Trial.
The hydralazine dose was given according with the acetylator phenotype, and valproate was dosed at 30 mg/kg/day. ...Preliminary results of this phase-II study suggest that the combination of hydralazine and valproate is a promising non-toxic and effective therapy fo …
The hydralazine dose was given according with the acetylator phenotype, and valproate was dosed at 30 mg/kg/day. ...Preliminary resul …
Effect of a Strategy of Comprehensive Vasodilation vs Usual Care on Mortality and Heart Failure Rehospitalization Among Patients With Acute Heart Failure: The GALACTIC Randomized Clinical Trial.
Kozhuharov N, Goudev A, Flores D, Maeder MT, Walter J, Shrestha S, Gualandro DM, de Oliveira Junior MT, Sabti Z, Müller B, Noveanu M, Socrates T, Ziller R, Bayés-Genís A, Sionis A, Simon P, Michou E, Gujer S, Gori T, Wenzel P, Pfister O, Conen D, Kapos I, Kobza R, Rickli H, Breidthardt T, Münzel T, Erne P, Mueller C; GALACTIC Investigators; Mueller C, Erne P, Müller B, Rickli H, Maeder M, Tavares de Oliveira M Jr, Münzel T, Bayés-Genís A, Sionis A, Goudev A, Dimov B, Hartwiger S, Arenja N, Glatz B, Herr N, Isenrich R, Mosimann T, Twerenbold R, Boeddinghaus J, Nestelberger T, Puelacher C, Freese M, Vögele J, Meissner K, Martin J, Strebel I, Wussler D, Schumacher C, Osswald S, Vogt F, Hilti J, Barata S, Schneider D, Schwarz J, Fitze B, Hartwiger S, Arenja N, Glatz B, Herr N, Isenrich R, Mosimann T, Twerenbold R, Boeddinghaus J, Nestelberger T, Puelacher C, Freese M, Vögele J, Meissner K, Martin J, Strebel I, Wussler D, Schumacher C, Osswald S, Vogt F, Hilti J, Barata S, Schneider D, Schwarz J, Fitze B, Arenja N, Rentsch K, Bossa A, Jallad S, Soeiro A, Georgiev D, Jansen T, Gebel G, Bossard M, Christ M. Kozhuharov N, et al. JAMA. 2019 Dec 17;322(23):2292-2302. doi: 10.1001/jama.2019.18598. JAMA. 2019. PMID: 31846016 Free PMC article. Clinical Trial.
Early intensive and sustained vasodilation was a comprehensive pragmatic approach of maximal and sustained vasodilation combining individualized doses of sublingual and transdermal nitrates, low-dose oral hydralazine for 48 hours, and rapid up-titration of angiotensin-conv …
Early intensive and sustained vasodilation was a comprehensive pragmatic approach of maximal and sustained vasodilation combining individual …
461 results